Liver Cancer Assay Gets CE-IVD Mark

Portugal-based Ophiomics has gained a CE-IVD mark for its HepatoPredict test, which uses machine learning algorithms, tumor gene expression and clinical variables to support liver transplantation decisions in patients with liver cancer.  

The test combines clinical parameters with molecular markers to assess tumor biology and predict which patients will benefit from a liver transplant and those for which a transplant would bring no benefit.

Under a commercialization deal inked with Ophiomics in February, Belgium-based Biocartis will launch the test as a manual kit in the European market. Depending on the commercial uptake of the manual kit, the companies aim to develop a fully automated version of the test.